A randomised, placebo controlled trial of prednisone in early Henoch Schonlein Purpura

ISRCTN ISRCTN85109383
DOI https://doi.org/10.1186/ISRCTN85109383
Secondary identifying numbers 95/25S(E)
Submission date
08/03/2004
Registration date
09/03/2004
Last edited
24/08/2007
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Haematological Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Adam Huber
Scientific

IWK Health Centre
5850 University Avenue
Halifax
B3J 3G9
Canada

Phone +1 902 470 8827
Email adamtheresa@hfx.eastlink.ca

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeTreatment
Scientific title
Study objectivesNot provided at time of registration
Ethics approval(s)Not provided at time of registration
Health condition(s) or problem(s) studiedHenoch Schonlein Purpura
InterventionIntervention:
Prednisone 2 mg/kg for 7 days, 75% on days 8 and 9, 50% on days 10 and 11 and 25% on days 12, 13, 14, then stopped.

Control:
Comparison group was an identical appearing placebo.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)Prednisone
Primary outcome measureNot provided at time of registration
Secondary outcome measuresNot provided at time of registration
Overall study start date01/09/1996
Completion date31/01/2000

Eligibility

Participant type(s)Patient
Age groupNot Specified
SexNot Specified
Target number of participants40
Key inclusion criteriaEligible participants were children between the ages of 2 and 15, presenting to the emergency room within 7 days of onset of Henoch Schonlein Purpura.

Children were excluded if:
1. Another explanation for purpura was present
2. They had a known underlying systemic vasculitis
3. They had been treated with any form of corticosteroids in the preceding month
4. They had a known chronic illness affecting the renal, gastrointestinal or immune systems
5. They had an active infection
6. They were experiencing a life-threatening complication of Henoch Schonlein Purpura
Key exclusion criteriaNot provided at time of registration
Date of first enrolment01/09/1996
Date of final enrolment31/01/2000

Locations

Countries of recruitment

  • Canada

Study participating centre

IWK Health Centre
Halifax
B3J 3G9
Canada

Sponsor information

Children's Hospital of Eastern Ontario Research Institute (CHEORI) (Canada)
Research organisation

401 Smyth Road
Room 139
Ottawa
K1H 8L1
Canada

Phone +1 613 737 7600 ext. 2686
Email brazeau@cheo.on.ca
ROR logo "ROR" https://ror.org/05nsbhw27

Funders

Funder type

Research organisation

Children's Hospital of Eastern Ontario Research Institute (CHEORI) (Canada) (ref: 95/25S[E])

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article Results 02/04/2004 Yes No